2022 World Conference on Lung Cancer (ePosters)-EP14.01-005. Weekly Sequential ACOCEV Chemotherapy (ADR, CTX, CBDCA, VP16, VCR) for Elderly - Poor PS SCLC Patients: An Observational Study

EP14.01-005. Weekly Sequential ACOCEV Chemotherapy (ADR, CTX, CBDCA, VP16, VCR) for Elderly - Poor PS SCLC Patients: An Observational Study

Back to course

Pdf Summary

This observational study evaluated the efficacy and toxicity of weekly sequential ACOCEV chemotherapy in elderly or poor performance status (PS) small cell lung cancer (SCLC) patients. A total of 59 patients were enrolled, with a median age of 71 years. The treatment consisted of Doxorubicin, Cyclophosphamide, Vincristine, Carboplatin, and VP16 administered every 28 days for 3-4 cycles.<br /><br />Among the evaluated patients, the overall disease control rate (partial response and stable disease) was 70.21%. Specifically, 61.70% of patients achieved a partial response, 8.51% had stable disease, and 29.79% had disease progression. The median time to progression was 5 months, and the median overall survival was 9.25 months.<br /><br />The ACOCEV chemotherapy regimen showed a high response rate and good tolerability. Grade 3-4 hematological toxicities, including febrile neutropenia and thrombocytopenia, occurred in a small percentage of patients. Grade 2 neurotoxicities (paresthesia), constipation, and alopecia were also observed in some patients.<br /><br />The study concluded that ACOCEV chemotherapy had comparable efficacy to conventional chemotherapy schedules but with a more favorable toxicity profile. It was deemed feasible for elderly or poor PS patients. However, further prospective studies are needed to confirm these findings.<br /><br />The study's results are represented in two figures. Figure A shows the overall survival of patients, with a median overall survival of 9 months. Figure B illustrates the response rate, with 61.70% of patients achieving a partial response and 29.79% experiencing disease progression.<br /><br />In summary, this observational study suggests that weekly sequential ACOCEV chemotherapy is effective and well-tolerated in elderly or poor PS SCLC patients, offering potential clinical benefits. Further research is needed to validate these findings.

Asset Subtitle

Antonio Santo

Meta Tag

Speaker Antonio Santo

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

Keywords

observational study

ACOCEV chemotherapy

efficacy

toxicity

elderly patients

small cell lung cancer

disease control rate

overall survival

chemotherapy schedules

clinical benefits